The US FDA has further revised its guidance on abbreviated new drug applications (ANDAs) and the deficiencies that can cause FDA to refuse-to-receive (RTR) an application. An RTR decision indicates that FDA determined that an ANDA is not substantially complete.
Read more “FDA revises refuse-to-receive guidance for ANDA submissions”